Dynavax TechnologiesDVAX
DVAX
About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Employees: 405
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
68% more call options, than puts
Call options by funds: $8.17M | Put options by funds: $4.87M
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 80
16% more capital invested
Capital invested by funds: $1.44B [Q3] → $1.67B (+$224M) [Q4]
2% more funds holding
Funds holding: 250 [Q3] → 254 (+4) [Q4]
0.32% more ownership
Funds ownership: 98.97% [Q3] → 99.29% (+0.32%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
3%
upside
Avg. target
$26
171%
upside
High target
$33
241%
upside
4 analyst ratings
3 positive
75%
0 neutral
0%
1 negative
25%
JMP Securities Roy Buchanan 21% 1-year accuracy 5 / 24 met price target | 221%upside $31 | Market Outperform Maintained | 7 May 2025 |
Goldman Sachs Paul Choi 56% 1-year accuracy 9 / 16 met price target | 3%upside $10 | Sell Maintained | 17 Apr 2025 |
Citizens Capital Markets Jason Butler 24% 1-year accuracy 9 / 38 met price target | 241%upside $33 | Market Outperform Maintained | 21 Feb 2025 |
HC Wainwright & Co. Edward White 17% 1-year accuracy 22 / 129 met price target | 221%upside $31 | Buy Reiterated | 21 Feb 2025 |
Financial journalist opinion
Based on 13 articles about DVAX published over the past 30 days
Neutral
Business Wire
1 day ago
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today issued a letter to shareholders in connection with its nomination of four highly qualified candidates for election to the Company's Board of Directors (the “Board”) at the 2025 Annual.
Neutral
PRNewsWire
5 days ago
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 12, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed an investor presentation with the Securities and Exchange Commission ("SEC") in connection with its 2025 Annual Meeting of Stockholders to be held on June 11, 2025.
Positive
Zacks Investment Research
1 week ago
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
PRNewsWire
1 week ago
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement in response to the investor presentation issued by Deep Track Capital ("Deep Track"): Deep Track's investor presentation demonstrates that Deep Track fundamentally does not understand how to run a successful commercial stage biotechnology company.
Neutral
Seeking Alpha
1 week ago
Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Negative
Zacks Investment Research
1 week ago
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.07 per share a year ago.
Neutral
PRNewsWire
1 week ago
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m.
Neutral
Business Wire
1 week ago
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.53% of the Company's outstanding shares, today released an investor presentation titled “The Path to Creating and Preserving Value at Dynavax.” The full presentation can be downloaded by clicking here. For more information, includi.
Neutral
PRNewsWire
2 weeks ago
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatitis B virus Findings released during Hepatitis Awareness Month underscore the importance of public education to address misunderstandings about hepatitis B and raise awareness of the Centers for Disease Control and Prevention (CDC) universal recommendation that eligible adults over 19 receive the hepatitis B vaccine Results will be discussed with a panel of hepatitis B experts during the May 27th LinkedIn Live event EMERYVILLE, Calif. , May 1, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the results of the Hepatitis B Perceptions and Insights Survey conducted by The Harris Poll, which found that Americans underestimate the serious consequences of hepatitis B and are largely unaware of the role vaccination plays in helping to prevent these consequences – including liver cancer.
Neutral
PRNewsWire
2 weeks ago
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today mailed a letter to its stockholders in connection with its 2025 Annual Meeting of Stockholders ("Annual Meeting") urging stockholders to vote the GOLD proxy card "FOR" all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun.
Charts implemented using Lightweight Charts™